Receive The Newest Study Notifications

The U.S. Food and Drug Administration (FDA) has awarded $2 million to support a Phase 2 clinical trial testing whether daily supplementation of vitamin D reduces the risk of respiratory complications in children and adolescents with sickle cell disease (SCD). Gary M....

NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and...

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S. study to evaluate the safety and performance of the Indigo System with CAT...

WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the first patient in its...

The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria. For patients who are suffering...

SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with atopic...

YTX-7739 represents a novel, first-in-class, potentially disease-modifying therapy Data from Phase 1 study expected in the first quarter of 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Yumanity Therapeutics, a company focused on protecting the vitality of the mind by...

NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and...

Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it...

CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced that it...

NEURO-PAIN MEDICAL CENTER is recruiting for a clinical research study to evaluate an investigational medication in people diagnosed with Parkinson’s disease who are experiencing symptoms such as seeing things/hearing things that may not actually be there. The study...

Investigational Therapy Designed to Engineer Patients’ Own Stem Cells to Produce Essential Protein CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced that the first patient has been dosed in the Company’s AVR-RD-04...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Data Presented at ID Week...

Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer Trials OCALA, FL / ACCESSWIRE / October 7, 2019 / AIM ImmunoTech Inc. (NYSE...

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced full enrollment of its Phase 2b study. On October 3, 2019, ILiAD Biotechnologies...

Median overall survival for ADXS-PSA in combination with KEYTRUDA® increased to 33.6 months from previously reported 21.1 months PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery,...

BEVERLY, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that management is finalizing documentation necessary to initiate the planned Phase 1...

- EVIDENCES IV trial meets primary efficacy end-points - Statistically significant 44.39 % reduction in ALT (alanine aminotransferase) observed with Saroglitazar Magnesium treated patients AHMEDABAD, India, Oct. 3, 2019 /PRNewswire/ -- Zydus Cadila, an...

Study evaluates clinical utility of 68Ga THP-PSMA PET/CT imaging in men with newly diagnosed and recurrent prostate cancer LONDON and BOSTON, Oct. 2, 2019 /PRNewswire/ -- Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer diagnosis...

CAMBRIDGE, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR)...